Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Jamrm LLC currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and is situated in 1 distinct art unit. This indicates a very streamlined prosecution profile where all active matters are concentrated in a single administrative location at the patent office.
The busiest examiner for the portfolio is KWON, JOHN SEUNGJAI, who is assigned 1 pending office action. As the total number of pending actions is 1, this examiner manages all of the company's current active cases. This arrangement suggests that the prosecution's success is tied to the specific requirements of this individual examiner. There are no other examiners involved in the portfolio's current active matters, which simplifies the communication chain.
With only 1 distinct art unit in play, the technical review is confined to a single specialized group. Practitioners should note the lack of examiner variety for these Biotechnology & Pharmaceuticals applications. The current 1 to 1 ratio of busiest examiner workload to total pending actions highlights this centralized approach, where every active filing is under the jurisdiction of KWON, JOHN SEUNGJAI.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KWON, JOHN SEUNGJAI | 1 | 44.9% | +20.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17697779 | IMMEDIATE POST-PROCEDURE RECOVERY FORMULATION AND METHOD | KWON, JOHN SEUNGJAI | 16d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17697779 | IMMEDIATE POST-PROCEDURE RECOVERY FORMULATION AND METHOD | KWON, JOHN SEUNGJAI | 1615 | §103 | Final Rejection | 16d overdue | Pending | Mar 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialJamrm LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
John Seungjai Kwon has the most, with 1 of Jamrm LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
